Bifogade filer
PDF
Kurs
+9,06%
Likviditet
0,27 MSEK
Kalender
| Est. tid* | ||
| 2026-02-26 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-28 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-06-19 | N/A | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2025-06-18 | N/A | Årsstämma |
| 2025-05-22 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-11-28 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-27 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-20 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2024-06-19 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-06 | - | Extra Bolagsstämma 2024 |
| 2024-03-05 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-19 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2023-06-16 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-01 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2022-05-31 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-31 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-31 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2021-05-28 | - | Årsstämma |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-29 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2019-05-28 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-01 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2018-05-31 | - | Årsstämma |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-01 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2017-05-31 | - | Årsstämma |
| 2017-05-31 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-24 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-24 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2016-05-23 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
| 2015-11-25 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-29 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2015-05-28 | - | Årsstämma |
| 2015-05-25 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-26 | - | Bokslutskommuniké 2014 |
| 2014-11-24 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-28 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-22 | - | Årsstämma |
| 2014-05-22 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-28 | - | Bokslutskommuniké 2013 |
| 2013-11-29 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-26 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-28 | - | Split AXIC A 4:1 |
| 2013-05-30 | - | Kvartalsrapport 2013-Q1 |
| 2013-05-21 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2013-05-20 | - | Årsstämma |
| 2013-02-28 | - | Bokslutskommuniké 2012 |
| 2012-11-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-30 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-28 | - | Kvartalsrapport 2012-Q1 |
| 2012-05-17 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2012-05-16 | - | Årsstämma |
| 2012-02-29 | - | Bokslutskommuniké 2011 |
| 2011-11-28 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-30 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-30 | - | Kvartalsrapport 2011-Q1 |
| 2011-05-10 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
| 2011-05-09 | - | Årsstämma |
| 2011-02-25 | - | Bokslutskommuniké 2010 |
| 2010-05-11 | - | X-dag ordinarie utdelning AXIC A 0.00 SEK |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Material |
| Industri | Plast, kemikalier & fetter |
aXichem AB (publ), (aXichem), the developer of innovative natural analogue feed additives and food supplement ingredients, today reports that GLP-Activate™, launched in April 2024 by Triquetra Health, is now one of the retailer's leading products and a key growth driver for aXichem's nutraceutical ingredient aXivite.
"GLP-Activate has exceeded every sales benchmark we set. Consumers are actively seeking science-backed solutions that mimic GLP-1 benefits without the side-effects reported for semaglutide injectables. aXivite allows them to preserve lean mass while reducing fat, delivering real metabolic advantages in a convenient capsule.", said Elias Chiatalas, CEO of SEE Nutrition, aXichem's commercial agent in the United States.
"SEE Nutrition anticipates that this weight-loss category will contribute approximately an additional 7 M SEK in aXivite sales for delivery over the next 12 months, supporting aXichem's sales for the 2025 financial year.", said Lucas Altepost, VP Sales and Marketing at aXichem.
Strong category tail-winds
U.S. retailers identify "nutritional support for GLP-1 users" and natural GLP-1 boosters as a leading 2025 wellness trend. The global GLP-1 analogue drugs market is projected to reach USD 47 billion in 2025, with complementary categories benefiting from halo demand.
Scientific validation of aXivite
Clinical research shows that phenylcapsaicin (aXivite) significantly reduces body-fat while preserving lean mass and supports gut-barrier integrity. Additional studies demonstrate improved aerobic capacity and metabolic efficiency.
About GLP-Activate™
GLP-Activate combines aXivite phenylcapsaicin with botanicals designed to stimulate endogenous GLP-1 release, helping users manage appetite and cravings while sustaining metabolic health. The once-daily capsule offers a drug-free alternative for consumers hesitant about prescription injectables amid growing media coverage of side-effects and supply shortages.
The information was submitted, through the care of the contact person below, for publication on
28 April 2025, at 9:00 AM CET.
Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
More about aXichem at www.axichem.com.